LifeSCi Acquisition in an 8-K filing said shareholders voted in favor of the business combination with Vincera Pharma.
The combined company is expected to have approximately $62 million in cash at closing, which Vincera reported today. Shares begin trading Dec. 24 on the Nasdaq under VINC. Read more.
